Starts & Stops: Respicardia Puts Sleep Apnea Device PAS On Snooze
Executive Summary
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the past month. This edition takes a closer look at Respicardia, which has cut short the post-approval study of its implantable sleep apnea device study.
You may also be interested in...
Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN
Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.
Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial
The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.